Terms: = Breast cancer AND ACSL6, FACL6, 23305, ENSG00000164398, KIAA0837, LACS5, ACS2, LACS2
5 results:
1. ACSL family: The regulatory mechanisms and therapeutic implications in cancer.
Quan J; Bode AM; Luo X
Eur J Pharmacol; 2021 Oct; 909():174397. PubMed ID: 34332918
[TBL] [Abstract] [Full Text] [Related]
2. Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance.
Yen MC; Kan JY; Hsieh CJ; Kuo PL; Hou MF; Hsu YL
Oncol Rep; 2017 Jun; 37(6):3253-3260. PubMed ID: 28498416
[TBL] [Abstract] [Full Text] [Related]
3. 17β-estradiol-induced ACSL4 protein expression promotes an invasive phenotype in estrogen receptor positive mammary carcinoma cells.
Belkaid A; Ouellette RJ; Surette ME
Carcinogenesis; 2017 Apr; 38(4):402-410. PubMed ID: 28334272
[TBL] [Abstract] [Full Text] [Related]
4. Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in cancer.
Chen WC; Wang CY; Hung YH; Weng TY; Yen MC; Lai MD
PLoS One; 2016; 11(5):e0155660. PubMed ID: 27171439
[TBL] [Abstract] [Full Text] [Related]
5. Dithiolethiones inhibit NF-κB activity via covalent modification in human estrogen receptor-negative breast cancer.
Switzer CH; Cheng RY; Ridnour LA; Murray MC; Tazzari V; Sparatore A; Del Soldato P; Hines HB; Glynn SA; Ambs S; Wink DA
Cancer Res; 2012 May; 72(9):2394-404. PubMed ID: 22436383
[TBL] [Abstract] [Full Text] [Related]
